HB002.1T / Zhejiang Huahai Pharma, Huaota Biopharm, Huabo Biopharmaceutical Technology - LARVOL DELTA

Characteristics of Bovine Enterovirus F in four provinces of China: isolation, pathogenicity and immunogenicity. (PubMed, Microb Pathog) - "Two strains, HN004-8 and HB002, were isolated in Madin-Darby bovine kidney (MDBK) cells and identified as BEV through reverse transcription-polymerase chain reaction (RT-PCR), transmission electron microscopy (TEM), indirect immunofluorescence assay (IFA), and viral growth kinetics analysis...Preliminary immunogenicity evaluation of an inactivated HN004-8 emulsion agent showed the induction of BEV-specific IgG and neutralizing antibodies in mice. In summary, this study isolated two BEV strains and provided molecular characterization of BEV isolates in China, which may provide potential candidate strains for further vaccine development."

Journal • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Interstitial Lung Disease • Oncology • Pneumonia • Respiratory Diseases

Pseudomonas algeriensis sp. nov.: A Promising Phosphate-Solubilizing Endophytic Bacterium Isolated from Legume Root Nodules in the Coastal Dunes of Northwest Algeria. (PubMed, Curr Microbiol) - "Analysis of the 16S rRNA gene sequence revealed that strain NR3T shared the highest pairwise sequence similarity with Pseudomonas canavaninivorans HB002T (99.6%), Pseudomonas alvandae SWRI17T (99.5%), Pseudomonas bijieensis L22-9T (99.5%), and Pseudomonas tehranensis SWRI196T (99.4%)...nov. is proposed."

Journal • Infectious Disease

A phase Ib trial of the VEGF fusion protein HB002.1T plus chemotherapy in patients with advanced solid tumors. (ASCO 2023) - P1 | " This study aimed to evaluate efficacy and safety of HB002.1T plus chemotherapy (mainly based on platinum, paclitaxel, gemcitabine, etc.) in advanced solid tumors. The Pts were well tolerated to 12mg/kg and 16mg/kg HB002.1T dose combined with chemotherapy, and HB002.1T showed acceptable safety profile. As well as, promising anti-tumor activity was observed in various tumors, especially in advanced ovarian cancer. More data is being accumulated, and confirmatory clinical trials are being prepared."

Clinical • Metastases • P1 data • Biliary Cancer • Cholangiocarcinoma • Gallbladder Cancer • Gastric Cancer • Gastrointestinal Cancer • Hematological Disorders • Hepatology • Leukopenia • Neutropenia • Oncology • Ovarian Cancer • Renal Disease • Solid Tumor • VEGFB

Pseudomonas canavaninivorans sp. nov., isolated from bean rhizosphere. (PubMed, Int J Syst Evol Microbiol) - "is proposed. The type strain is HB002 (=DSM 112525=LMG 32336)."

Journal • CAT

[VIRTUAL] INTERIM RESULTS OF HBV001, A PHASE 1 STUDY EVALUATING THE SAFETY AND TOLERABILITY OF THERAPEUTIC VACCINATION WITH ChAdOx1-HBV IN HEALTHY VOLUNTEERS AND PATIENTS WITH CHRONIC HEPATITIS B INFECTION (AASLD 2021) - P1, P1b/2a | "Vaccination with ChAdOx1- HBV is well tolerated and induces T cell responses in healthy volunteers and patients with chronic HBV. A phase II study of ChAdOx1-HBV in combination with MVA-HBV and the anti- PD1 agent Nivolumab in patients with chronic HBV is ongoing (HBV002, NCT04778904)."

Clinical • P1 data • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Pain • IFNG

A Study of Injection HB002.1T in Subjects With Solid Tumor (clinicaltrials.gov) - P1; N=27; Completed; Sponsor: Huabo Biopharm Co., Ltd.; Active, not recruiting ➔ Completed

Trial completion • Oncology • Solid Tumor

Complete Genome Sequences of Thermus thermophilus Strains HB5002 and HB5008, Isolated from Mine Hot Spring in Japan. (PubMed, Microbiol Resour Announc) - "We isolated Thermus thermophilus strains HB5002 and HB5008 from Mine Hot Spring in Japan. Whole-genome sequencing revealed that they showed ∼100% average nucleotide identity to each other, ≥98.53% to the T. thermophilus strains originating from the same spot but ≤97.64% to the T. thermophilus strains from geographically different places in Japan."

Journal

A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor (clinicaltrials.gov) - P1; N=72; Recruiting; Sponsor: Huabo Biopharm Co., Ltd.

Clinical • Combination therapy • New P1 trial • Cholangiocarcinoma • Lung Cancer • Oncology • Solid Tumor

A Study of Injection HB002.1T in Subjects With Solid Tumor (clinicaltrials.gov) - P1; N=27; Active, not recruiting; Sponsor: Huabo Biopharm Co., Ltd.; Trial completion date: Feb 2021 ➔ Aug 2021; Trial primary completion date: Feb 2021 ➔ Jun 2021

Clinical • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

[VIRTUAL] NEUROPROTECTION OF LOW DOSE CARBON MONOXIDE IN GENETIC AND TOXIN MODELS OF PARKINSON’S DISEASE (ADPD 2021) - "AAV-aSyn rats treated with HBI002 retained 74±12% (SD) of right striatal dopamine versus left, compared to 36±7% in vehicle-treated rats (p=0.03). Low-dose CO protects nigral dopamine neurons, preserves striatal dopamine content, and reduces aSyn pathology in animal models of PD. Low dose CO may have disease-modifying activity in PD."

CNS Disorders • Movement Disorders • Parkinson's Disease

A Study of Injection HB002.1T in Subjects With Solid Tumor (clinicaltrials.gov) - P1; N=27; Active, not recruiting; Sponsor: Huabo Biopharm Co., Ltd.; Trial completion date: Nov 2020 ➔ Feb 2021; Trial primary completion date: Oct 2020 ➔ Feb 2021

Clinical • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Study of Injection HB002.1T in Subjects With Solid Tumor (clinicaltrials.gov) - P1; N=27; Active, not recruiting; Sponsor: Huabo Biopharm Co., Ltd.; Recruiting ➔ Active, not recruiting; Trial completion date: Jun 2020 ➔ Nov 2020; Trial primary completion date: May 2020 ➔ Oct 2020

Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Study of Injection HB002.1T in Subjects With Solid Tumor (clinicaltrials.gov) - P1; N=30; Recruiting; Sponsor: Huabo Biopharm Co., Ltd.; Trial primary completion date: Aug 2019 ➔ May 2020

Clinical • Trial primary completion date